;PMID: 1581890
;source_file_1192.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:43..135] = [t:43..135]
;2)section:[e:139..208] = [t:139..208]
;3)section:[e:212..288] = [t:212..288]
;4)sentence:[e:292..528] = [t:292..528]
;5)sentence:[e:529..707] = [t:529..707]
;6)sentence:[e:708..876] = [t:708..876]
;7)sentence:[e:877..954] = [t:877..954]
;8)sentence:[e:955..1141] = [t:955..1141]
;9)sentence:[e:1142..1240] = [t:1142..1240]
;10)sentence:[e:1241..1395] = [t:1241..1395]
;11)sentence:[e:1396..1604] = [t:1396..1604]
;12)sentence:[e:1606..1769] = [t:1606..1769]
;13)section:[e:1773..1817] = [t:1773..1817]

;section 0 Span:0..38
;Cancer Res  1992 May 15;52(10):2777-81
(SEC
  (FRAG (NN:[0..6] Cancer) (NNP:[7..10] Res) (CC:[12..16] 1992)
        (NNP:[17..20] May) (CD:[21..27] 15;52-LRB-) (CD:[27..29] 10)
        (-RRB-:[29..30] -RRB-) (CD:[30..35] :2777) (CC:[35..36] -)
        (CD:[36..38] 81)))

;sentence 1 Span:43..135
;Clinical implications of K-ras mutations in malignant epithelial tumors of
;the  endometrium.
;[68..73]:gene-rna:"K-ras"
;[87..134]:malignancy:"malignant epithelial tumors of the  endometrium"
(SENT
  (NP-HLN
    (NP (JJ:[43..51] Clinical) (NNS:[52..64] implications))
    (PP (IN:[65..67] of)
      (NP
        (NP (NN:[68..73] K-ras) (NNS:[74..83] mutations))
        (PP (IN:[84..86] in)
          (NP
            (NP (JJ:[87..96] malignant) (JJ:[97..107] epithelial)
                (NNS:[108..114] tumors))
            (PP (IN:[115..117] of)
              (NP (DT:[118..121] the) (NN:[123..134] endometrium)))))))
    (.:[134..135] .)))

;section 2 Span:139..208
;Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garrett CT.
(SEC
  (FRAG (NNP:[139..147] Mizuuchi) (NNP:[148..149] H) (,:[149..150] ,)
        (NNP:[151..156] Nasim) (NNP:[157..159] S,) (NNP:[160..164] Kudo)
        (NNP:[165..167] R,) (NNP:[168..178] Silverberg) (NNP:[179..181] SG)
        (,:[181..182] ,) (NNP:[183..193] Greenhouse) (NNP:[194..196] S,)
        (NNP:[197..204] Garrett) (NNP:[205..208] CT.)))

;section 3 Span:212..288
;Department of Pathology, George Washington University, Washington, DC 20037.
(SEC
  (FRAG (NNP:[212..222] Department) (IN:[223..225] of)
        (NNP:[226..235] Pathology) (,:[235..236] ,) (NNP:[237..243] George)
        (NNP:[244..254] Washington) (NNP:[255..265] University) (,:[265..266] ,)
        (NNP:[267..277] Washington) (,:[277..278] ,) (NNP:[279..281] DC)
        (CD:[282..287] 20037) (.:[287..288] .)))

;sentence 4 Span:292..528
;Tumorigenesis in humans and experimental animals appears to involve the 
;activation of ras protooncogenes for a number of organ systems and seems to
;be  important to the development of the metastatic phenotype in several model
; systems.
;[379..382]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[292..305] Tumorigenesis))
      (PP (IN:[306..308] in)
        (NP
          (NP (NNS:[309..315] humans))
          (CC:[316..319] and)
          (NP (JJ:[320..332] experimental) (NNS:[333..340] animals)))))
    (VP
      (VP (VBZ:[341..348] appears)
        (S
          (NP-SBJ-1 (-NONE-:[348..348] *))
          (VP (TO:[349..351] to)
            (VP (VB:[352..359] involve)
              (NP
                (NP (DT:[360..363] the) (NN:[365..375] activation))
                (PP (IN:[376..378] of)
                  (NP
                    (NP (NN:[379..382] ras) (NNS:[383..397] protooncogenes))
                    (PP (IN:[398..401] for)
                      (NP
                        (NP (DT:[402..403] a) (NN:[404..410] number))
                        (PP (IN:[411..413] of)
                          (NP (NN:[414..419] organ) (NNS:[420..427] systems))))))))))))
      (CC:[428..431] and)
      (VP (VBZ:[432..437] seems)
        (S
          (NP-SBJ-1 (-NONE-:[437..437] *))
          (VP (TO:[438..440] to)
            (VP (VB:[441..443] be)
              (ADJP-PRD (JJ:[445..454] important)
                (PP (TO:[455..457] to)
                  (NP
                    (NP (DT:[458..461] the) (NN:[462..473] development))
                    (PP (IN:[474..476] of)
                      (NP (DT:[477..480] the) (JJ:[481..491] metastatic)
                          (NN:[492..501] phenotype))))))
              (PP (IN:[502..504] in)
                (NP (JJ:[505..512] several) (NN:[513..518] model)
                    (NNS:[520..527] systems))))))))
    (.:[527..528] .)))

;sentence 5 Span:529..707
;Clinically, the presence of activated ras protooncogenes has been  reported
;to be a negative prognostic factor in the myelodysplastic syndrome and  in
;adenocarcinoma of the lung.
;[567..570]:gene-rna:"ras"
;[647..671]:malignancy:"myelodysplastic syndrome"
;[680..706]:malignancy:"adenocarcinoma of the lung"
(SENT
  (S
    (ADVP (RB:[529..539] Clinically))
    (,:[539..540] ,)
    (NP-SBJ-1
      (NP (DT:[541..544] the) (NN:[545..553] presence))
      (PP (IN:[554..556] of)
        (NP (VBN:[557..566] activated) (NN:[567..570] ras)
            (NNS:[571..585] protooncogenes))))
    (VP (VBZ:[586..589] has)
      (VP (VBN:[590..594] been)
        (VP (VBN:[596..604] reported)
          (S
            (NP-SBJ-1 (-NONE-:[604..604] *))
            (VP (TO:[605..607] to)
              (VP (VB:[608..610] be)
                (NP-PRD (DT:[611..612] a) (JJ:[613..621] negative)
                        (JJ:[622..632] prognostic) (NN:[633..639] factor))
                (PP
                  (PP (IN:[640..642] in)
                    (NP (DT:[643..646] the)
                       (JJ:[647..662] myelodysplastic) (NN:[663..671] syndrome)))
                  (CC:[672..675] and)
                  (PP (IN:[677..679] in)
                    (NP
                      (NP (NN:[680..694] adenocarcinoma))
                      (PP (IN:[695..697] of)
                        (NP (DT:[698..701] the) (NN:[702..706] lung))))))))))))
    (.:[706..707] .)))

;sentence 6 Span:708..876
;In the present study we examined 49 cases of  endometrial carcinoma for
;mutations in the first exon of K-ras using the  polymerase chain reaction and
;direct sequencing.
;[754..775]:malignancy:"endometrial carcinoma"
;[780..789]:variation-event:"mutations"
;[797..807]:variation-location:"first exon"
;[811..816]:gene-rna:"K-ras"
;[828..838]:gene-protein:"polymerase"
(SENT
  (S
    (PP (IN:[708..710] In)
      (NP (DT:[711..714] the) (JJ:[715..722] present) (NN:[723..728] study)))
    (NP-SBJ (PRP:[729..731] we))
    (VP (VBD:[732..740] examined)
      (NP
        (NP (CD:[741..743] 49) (NNS:[744..749] cases))
        (PP (IN:[750..752] of)
          (NP (JJ:[754..765] endometrial) (NN:[766..775] carcinoma))))
      (PP (IN:[776..779] for)
        (NP
          (NP (NNS:[780..789] mutations))
          (PP (IN:[790..792] in)
            (NP
              (NP (DT:[793..796] the)
                 (JJ:[797..802] first) (NN:[803..807] exon))
              (PP (IN:[808..810] of)
                (NP (NN:[811..816] K-ras)))))))
      (S-ADV
        (NP-SBJ (-NONE-:[816..816] *))
        (VP (VBG:[817..822] using)
          (NP
            (NP (DT:[823..826] the) (NN:[828..838] polymerase)
                (NN:[839..844] chain) (NN:[845..853] reaction))
            (CC:[854..857] and)
            (NP (JJ:[858..864] direct) (NN:[865..875] sequencing))))))
    (.:[875..876] .)))

;sentence 7 Span:877..954
;Mutations in codon 12 or 13 of  K-ras were detected in 6 of 49 cases
;(12.2%).
;[877..886]:variation-event:"Mutations"
;[890..898]:variation-location:"codon 12"
;[890..895]...[902..904]:variation-location:"codon"..."13"
;[909..914]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-2
      (NP (NNS:[877..886] Mutations))
      (PP (IN:[887..889] in)
        (NP
          (NP
            (NP
              (NML-1 (NN:[890..895] codon))
              (CD:[896..898] 12))
            (CC:[899..901] or)
            (NP
              (NML-1 (-NONE-:[901..901] *P*))
              (CD:[902..904] 13)))
          (PP (IN:[905..907] of)
            (NP (NN:[909..914] K-ras))))))
    (VP (VBD:[915..919] were)
      (VP (VBN:[920..928] detected)
        (NP-2 (-NONE-:[928..928] *))
        (PP (IN:[929..931] in)
          (NP
            (NP (CD:[932..933] 6))
            (PP (IN:[934..936] of)
              (NP (CD:[937..939] 49) (NNS:[940..945] cases)
                (PRN (-LRB-:[946..947] -LRB-)
                  (NP (CD:[947..951] 12.2) (NN:[951..952] %))
                  (-RRB-:[952..953] -RRB-))))))))
    (.:[953..954] .)))

;sentence 8 Span:955..1141
;These six cases consisted of five  endometrioid endometrial carcinomas, each
;of which had a mutation in codon 12,  and one case of clear cell carcinoma,
;which had a mutation in codon 13.
;[990..1025]:malignancy:"endometrioid endometrial carcinomas"
;[1047..1055]:variation-event:"mutation"
;[1059..1067]:variation-location:"codon 12"
;[1086..1106]:malignancy:"clear cell carcinoma"
;[1120..1128]:variation-event:"mutation"
;[1132..1140]:variation-location:"codon 13"
(SENT
  (S
    (NP-SBJ (DT:[955..960] These) (CD:[961..964] six) (NNS:[965..970] cases))
    (VP (VBD:[971..980] consisted)
      (PP-CLR (IN:[981..983] of)
        (NP
          (NP
            (NP (CD:[984..988] five)
               (JJ:[990..1002] endometrioid) (JJ:[1003..1014] endometrial)
               (NNS:[1015..1025] carcinomas))
            (,:[1025..1026] ,)
            (SBAR
              (WHNP-1
                (NP (DT:[1027..1031] each))
                (WHPP (IN:[1032..1034] of)
                  (WHNP (WDT:[1035..1040] which))))
              (S
                (NP-SBJ-1 (-NONE-:[1040..1040] *T*))
                (VP (VBD:[1041..1044] had)
                  (NP
                    (NP (DT:[1045..1046] a) (NN:[1047..1055] mutation))
                    (PP-LOC (IN:[1056..1058] in)
                      (NP (NN:[1059..1064] codon) (CD:[1065..1067] 12))))))))
          (,:[1067..1068] ,) (CC:[1070..1073] and)
          (NP
            (NP
              (NP (CD:[1074..1077] one) (NN:[1078..1082] case))
              (PP (IN:[1083..1085] of)
                (NP (JJ:[1086..1091] clear) (NN:[1092..1096] cell)
                    (NN:[1097..1106] carcinoma))))
            (,:[1106..1107] ,)
            (SBAR
              (WHNP-2 (WDT:[1108..1113] which))
              (S
                (NP-SBJ-2 (-NONE-:[1113..1113] *T*))
                (VP (VBD:[1114..1117] had)
                  (NP
                    (NP (DT:[1118..1119] a) (NN:[1120..1128] mutation))
                    (PP-LOC (IN:[1129..1131] in)
                      (NP (NN:[1132..1137] codon) (CD:[1138..1140] 13)))))))))))
    (.:[1140..1141] .)))

;sentence 9 Span:1142..1240
;In our  study the presence of mutations in K-ras appeared to be an
;unfavorable  prognostic factor.
;[1185..1190]:gene-rna:"K-ras"
(SENT
  (S
    (PP (IN:[1142..1144] In)
      (NP (PRP$:[1145..1148] our) (NN:[1150..1155] study)))
    (NP-SBJ
      (NP (DT:[1156..1159] the) (NN:[1160..1168] presence))
      (PP (IN:[1169..1171] of)
        (NP (NNS:[1172..1181] mutations)))
      (PP (IN:[1182..1184] in)
        (NP (NN:[1185..1190] K-ras))))
    (VP (VBD:[1191..1199] appeared)
      (S
        (NP-SBJ (-NONE-:[1199..1199] *))
        (VP (TO:[1200..1202] to)
          (VP (VB:[1203..1205] be)
            (NP-PRD (DT:[1206..1208] an) (JJ:[1209..1220] unfavorable)
                    (JJ:[1222..1232] prognostic) (NN:[1233..1239] factor))))))
    (.:[1239..1240] .)))

;sentence 10 Span:1241..1395
;Three of six patients with the mutation died during  follow-up, while only 7%
;of the 43 patients without K-ras mutations expired  during this same period.
;[1272..1280]:variation-event:"mutation"
;[1346..1351]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1241..1246] Three))
      (PP (IN:[1247..1249] of)
        (NP
          (NP (CD:[1250..1253] six) (NNS:[1254..1262] patients))
          (PP (IN:[1263..1267] with)
            (NP (DT:[1268..1271] the) (NN:[1272..1280] mutation))))))
    (VP (VBD:[1281..1285] died)
      (PP-TMP (IN:[1286..1292] during)
        (NP (VB:[1294..1300] follow) (HYPH:[1300..1301] -) (RP:[1301..1303] up)))
      (,:[1303..1304] ,)
      (SBAR-ADV (IN:[1305..1310] while)
        (S
          (NP-SBJ
            (NP (RB:[1311..1315] only) (CD:[1316..1317] 7) (NN:[1317..1318] %))
            (PP (IN:[1319..1321] of)
              (NP
                (NP (DT:[1322..1325] the) (CD:[1326..1328] 43)
                    (NNS:[1329..1337] patients))
                (PP (IN:[1338..1345] without)
                  (NP (NN:[1346..1351] K-ras) (NNS:[1352..1361] mutations))))))
          (VP (VBD:[1362..1369] expired)
            (PP-TMP (IN:[1371..1377] during)
              (NP (DT:[1378..1382] this) (JJ:[1383..1387] same)
                  (NN:[1388..1394] period)))))))
    (.:[1394..1395] .)))

;sentence 11 Span:1396..1604
;In multivariate analysis using the Cox proportional  hazard model, K-ras
;activation appeared to be an independent risk factor when  compared with
;clinical stage, depth of myometrial invasion, and patient age.
;[1463..1468]:gene-rna:"K-ras"
(SENT
  (S
    (PP (IN:[1396..1398] In)
      (NP
        (NP (JJ:[1399..1411] multivariate) (NN:[1412..1420] analysis))
        (VP (VBG:[1421..1426] using)
          (NP (DT:[1427..1430] the)
            (NML (NNP:[1431..1434] Cox) (JJ:[1435..1447] proportional)
                 (NN:[1449..1455] hazard))
            (NN:[1456..1461] model)))))
    (,:[1461..1462] ,)
    (NP-SBJ-1 (NN:[1463..1468] K-ras) (NN:[1469..1479] activation))
    (VP (VBD:[1480..1488] appeared)
      (S
        (NP-SBJ-1 (-NONE-:[1488..1488] *))
        (VP (TO:[1489..1491] to)
          (VP (VB:[1492..1494] be)
            (NP-PRD (DT:[1495..1497] an) (JJ:[1498..1509] independent)
                    (NN:[1510..1514] risk) (NN:[1515..1521] factor))
            (SBAR-ADV
              (WHADVP-3 (WRB:[1522..1526] when))
              (S
                (NP-SBJ-2 (-NONE-:[1526..1526] *))
                (VP (VBN:[1528..1536] compared)
                  (NP-2 (-NONE-:[1536..1536] *))
                  (PP-CLR (IN:[1537..1541] with)
                    (NP
                      (NP (JJ:[1542..1550] clinical) (NN:[1551..1556] stage))
                      (,:[1556..1557] ,)
                      (NP
                        (NP (NN:[1558..1563] depth))
                        (PP (IN:[1564..1566] of)
                          (NP (JJ:[1567..1577] myometrial)
                              (NN:[1578..1586] invasion))))
                      (,:[1586..1587] ,) (CC:[1588..1591] and)
                      (NP (NN:[1592..1599] patient) (NN:[1600..1603] age))))
                  (ADVP-TMP-3 (-NONE-:[1603..1603] *T*)))))))))
    (.:[1603..1604] .)))

;sentence 12 Span:1606..1769
;Thus, our findings support the hypothesis that K-ras protooncogene activation
; plays an important role in determining the aggressiveness of endometrial 
;carcinoma.
;[1653..1658]:gene-rna:"K-ras"
;[1746..1768]:malignancy:"endometrial  carcinoma"
(SENT
  (S
    (ADVP (RB:[1606..1610] Thus))
    (,:[1610..1611] ,)
    (NP-SBJ (PRP$:[1612..1615] our) (NNS:[1616..1624] findings))
    (VP (VBP:[1625..1632] support)
      (NP
        (NP (DT:[1633..1636] the) (NN:[1637..1647] hypothesis))
        (SBAR (IN:[1648..1652] that)
          (S
            (NP-SBJ (NN:[1653..1658] K-ras) (NN:[1659..1672] protooncogene)
                    (NN:[1673..1683] activation))
            (VP (VBZ:[1685..1690] plays)
              (NP (DT:[1691..1693] an) (JJ:[1694..1703] important)
                  (NN:[1704..1708] role))
              (PP (IN:[1709..1711] in)
                (S-NOM
                  (NP-SBJ (-NONE-:[1711..1711] *))
                  (VP (VBG:[1712..1723] determining)
                    (NP
                      (NP (DT:[1724..1727] the) (NN:[1728..1742] aggressiveness))
                      (PP (IN:[1743..1745] of)
                        (NP (JJ:[1746..1757] endometrial)
                            (NN:[1759..1768] carcinoma))))))))))))
    (.:[1768..1769] .)))

;section 13 Span:1773..1817
;PMID: 1581890 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1773..1777] PMID) (::[1777..1778] :) (CD:[1779..1786] 1581890)
        (IN:[1787..1788] -LSB-) (NNP:[1788..1794] PubMed) (HYPH:[1795..1796] -)
        (JJ:[1797..1804] indexed) (IN:[1805..1808] for)
        (NNP:[1809..1817] MEDLINE-RSB-)))
